Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia
C Fozza, G Corda, F Barraqueddu, P Virdis, S Contini… - Leukemia Research, 2015 - Elsevier
Patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with
multilineage dysplasia show several immunological abnormalities. In this clinical setting, by
combining flow cytometry and CDR3 spectratyping we monitored the kinetic of the T-cell
repertoire during Azacitidine treatment, in order to explore its potential ability to reverse the
immune derangement typical of these disorders. We firstly demonstrated by flow cytometry
an increase in both CD4+ and CD8+ T-cell frequencies after starting treatment. Moreover …
multilineage dysplasia show several immunological abnormalities. In this clinical setting, by
combining flow cytometry and CDR3 spectratyping we monitored the kinetic of the T-cell
repertoire during Azacitidine treatment, in order to explore its potential ability to reverse the
immune derangement typical of these disorders. We firstly demonstrated by flow cytometry
an increase in both CD4+ and CD8+ T-cell frequencies after starting treatment. Moreover …
